12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Other News

NeuroSearch cardiovascular news

NeuroSearch will spin out newco Acesion Pharma ApS to focus on developing products to treat atrial fibrillation (AF) based on NeuroSearch's sodium and potassium ion channels program. Acesion will receive an option to license new and existing compounds developed within the program.

If the option is exercised, NeuroSearch would receive an upfront minority ownership in Acesion. NeuroSearch would also...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >